Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7 Mln
P/E Ratio
--
P/B Ratio
0.22
Industry P/E
28.06
Debt to Equity
0.32
ROE
-0.23 %
ROCE
--
Div. Yield
0 %
Book Value
4.99
EPS
-1.1
CFO
$-154.68 Mln
EBITDA
$-60.35 Mln
Net Profit
$-310.56 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aytu BioScience Inc (AYTU)
| -34.71 | -9.76 | -34.71 | -60.36 | -55.76 | -66.91 | -74.62 |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Aytu BioScience Inc (AYTU)
| -39.89 | -24.87 | -85.93 | -77.42 | -38.51 | 22.73 | -98.18 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,904.81 | -- | 38.11 | |
| 71.71 | 7,574.08 | 58.3 | 23.56 | |
| 59.16 | 11,448.88 | 394.4 | 0.76 | |
| 8.13 | 9,704.70 | -- | -3.24 |
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder... (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado. Read more
Chairman & CEO
Mr. Joshua R. Disbrow
Chairman & CEO
Mr. Joshua R. Disbrow
Headquarters
Denver, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aytu BioScience Inc (AYTU) stood at $ 180 Mln as on 31-Dec-24
The share price of Aytu BioScience Inc (AYTU) is $1.11 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Aytu BioScience Inc (AYTU) has given a return of -55.76% in the last 3 years.
Aytu BioScience Inc (AYTU) has a market capitalisation of $ 7 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Aytu BioScience Inc (AYTU) is 0.22 times as on 25-Apr-2025, a 96% discount to its peers’ median range of 5.04 times.
Since, TTM earnings of Aytu BioScience Inc (AYTU) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aytu BioScience Inc (AYTU) and enter the required number of quantities and click on buy to purchase the shares of Aytu BioScience Inc (AYTU).
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
The CEO & director of Mr. Joshua R. Disbrow. is Aytu BioScience Inc (AYTU), and CFO & Sr. VP is Mr. Joshua R. Disbrow.
There is no promoter pledging in Aytu BioScience Inc (AYTU).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Aytu BioScience Inc (AYTU) | Ratios |
|---|---|
|
Return on equity(%)
|
-17.94
|
|
Operating margin(%)
|
-9.62
|
|
Net Margin(%)
|
-7.63
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Aytu BioScience Inc (AYTU) was $0 Mln.
$0.06
(
